TEVA/MYL—“Regulatory blockage” as in objections from antitrust regulators. There are only five large global generic-drug companies remaining, so combining two of them is likely to be viewed as anticompetitive by at least one regulatory body who has veto power over the deal.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”